Company: CNTB
Filing Date: 2025-06-10
Form Type: F-3
Source: 0001193125-25-138482
Chunk: 130

Company: Connect Biopharma Holdings Ltd
Filing Date: 2025-06-10
Form: F-3
Chunk 130
---
 consult their tax advisors regarding the application of the United States information reporting and backup withholding rules.

Backup withholding is not an additional tax. Amounts withheld as backup withholding may be credited against your U.S. federal
income tax liability, and you may obtain a refund of any excess amounts withheld under the backup withholding rules by timely filing the appropriate claim for refund with the U.S. Internal Revenue Service and furnishing any required information.

Additional Reporting Requirements

Certain U.S. Holders who are individuals (and certain entities) are required to report information relating to an interest in
our ADSs or Ordinary Shares, subject to certain exceptions (including an exception for ADSs and Ordinary Shares held in accounts maintained by certain financial institutions). U.S. Holders should consult their tax advisors regarding the effect, if
any, of these rules on the ownership and disposition of our ADSs or Ordinary Shares.

45

PLAN OF DISTRIBUTION

We have entered into a Sales Agreement with the Sales Agent under which we may issue and sell up to $150,000,000 of the ADSs
from time to time through Cantor as our Sales Agent. Sales of the ADSs, if any, will be made by any method that is deemed to be an “at the market offering” as defined in Rule 415 under the Securities Act, including sales made directly on
or through the Nasdaq Global Market, on or through any other existing trading market for the ADSs or to or through a market maker. As of June 10, 2025, we have not sold any ADSs under the Sales Agreement.

The Sales Agent will offer the ADSs subject to the terms and conditions of the Sales Agreement on a daily basis or as
otherwise agreed upon by us and the Sales Agent. We will designate the maximum number or amount of ADSs to be sold through the Sales Agent on a daily basis or otherwise determine such maximum number or amount together with the Sales Agent. Subject
to the terms and conditions of the Sales Agreement, the Sales Agent will use commercially reasonable efforts consistent with its normal trading and sales practices to sell on our behalf all of the ADSs requested to be sold by us. We may instruct the
Sales Agent not to sell ADSs if the sales cannot be effected at or above a minimum price designated by us in any such instruction. The Sales Agent or we may suspend the offering of the ADSs being made under the Sales Agreement upon proper notice to
the other parties. The Sales Agent and we each have the right, by giving written notice